‘Katja is a highly professional PR expert. She is extremely well networked, has a strong understanding of the PR processes in life sciences and has repeatedly delivered high quality outcomes for client companies.’

Douglas Thomson
CEO of Pneumagen

Objectives

  • To position Pneumagen’s platform technology as delivering value in treating infectious diseases, including COVID-19, by targeting the human glycome, leading to raised awareness with potential partners and investors
  • To highlight Pneumagen’s Neumifil™ as a potential anti-viral for the the treatment of COVID-19 with the local Scottish media
  • Raising awareness of the company’s £4 million fundraising to support clinical trials in COVID-19

Strategy

  • Supported development of new corporate materials, such as a new website, investor deck and press releases and setting up social media strategy
  • Coordinated communications activities with third parties including the University of St Andrews and local investors
  • Drafting press releases and associated key messaging, leveraging relationship with St Andrews’ to support local Scottish science story

Results

  • Secured significant coverage in Scottish national and broadcast media, showing the company is committed to supporting the global effort to treat the coronavirus pandemic
  • Supported a GBP 4m investment in May to progress Neumifil™ as a treatment for Covid-19 in human clinical trials